Poor Outcome With Anti-Programmed Death-Ligand 1 (PD-L1) Antibody Due to Poor Pharmacokinetic Properties in PD-1/PD-L1 Blockade-Sensitive Mouse Models

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1136/jitc-2019-000400
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma

Journal of Cancer
Oncology
2017English

PD-1 Receptor (PDCD1; PD-1; CD279); Programmed Cell Death 1 Ligand 1 (CD274 Molecule; PD-L1; B7-H1)

Science-Business eXchange
2010English

Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1)

American Journal of Surgical Pathology
AnatomyForensic MedicinePathologySurgery
2016English

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors

Frontiers in Oncology
Cancer ResearchOncology
2019English

Diverse Cutaneous Adverse Eruptions Caused by Anti-Programmed Cell Death-1 (PD-1) and Anti-Programmed Cell Death Ligand-1 (PD-L1) Immunotherapies: Clinical Features and Management

Therapeutic Advances in Medical Oncology
Oncology
2018English

Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2013English

Oncolytic Virus and PD-1/PD-L1 Blockade Combination Therapy

Oncolytic Virotherapy
2018English

Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation

Cancer immunology research
Cancer ResearchImmunology
2018English

2241. Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(pd-L1) Inhibitor Therapy in HIV Patients With Advanced Cancer

Open Forum Infectious Diseases
OncologyNeurology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy